Tuesday morning brings five major stories, and five ways to profit. Here's what happened and how you make money from it. ...

Siemens Healthineers (OTCPK:SEMH.F) FY Conference January 13, 2026 06:00 PM ET Company ParticipantsJochen Schmitz - CFODavid Adlington - Head of MedTech ResearchBernd Montag - CEODavid AdlingtonGood afternoon, everybody. I'm David Adlington, and I head up the J.P. Morgan research team for MedTech in London. For J.P. Morgan, it's my pleasure to introduce Dr. Montag, and we've got Jochen the CFO as well from Healthineers. There'll be a presentation and then a Q&A afterwards. Thank you.Bernd MontagAgain, so th ...

Siemens Healthineers AG J.P. Morgan Healthcare Conference, January 13, 2026 Unrestricted © Siemens Healthineers, 2026 Unrestricted © Siemens Healthineers, 2025 This webcast has been provided solely for use at this meeting. By attending the meeting or accessing this webcast, you agree to be bound by the following limitations. This webcast is provided in conjunction with an oral presentation and should not be taken out of context. This webcast serves for information purposes only and the information contained ...

Group 1 - Philips N.V. is characterized as a "set it and forget it" company, indicating a stable investment with long-term potential in the imaging and image-guided therapies sectors [1] - The company is recognized as one of the world leaders in its fields, which enhances its attractiveness to investors [1] Group 2 - The article emphasizes the importance of conducting due diligence and research prior to any investment, highlighting that the author is not providing financial advice [2] - It is noted that investing in European and Scandinavian stocks may involve specific withholding tax risks, which investors should consider [2]

Boston Scientific Corporation (NYSE:BSX) is one of the best healthcare AI stocks to buy now. On December 12, TD Cowen reaffirmed a Buy rating on Boston Scientific Corporation (NYSE:BSX) and kept a $115 price target. The firm went a step further to name Boston Scientific their “Best Idea for 2026.” TD Cowen Names Boston Scientific (BSX) Top 2026 Pick, Reaffirms Buy Image: Courtesy of Boston Scientific TD Cowen called Boston Scientific “the most attractive growth story in the medical devices sector.” The ...

Core Viewpoint - Veeva Systems Inc. is considered one of the top healthcare AI stocks to invest in, despite some customer migrations from its legacy CRM platform, which are viewed as manageable and not detrimental to the company's overall momentum [1]. Group 1: Company Performance and Revenue - Veeva currently serves 18 of the top 20 pharmaceutical companies with its CRM tools, but now expects only 14 to migrate to the newer Veeva Vault CRM, a slight decrease from previous expectations [2]. - CRM revenue constitutes approximately 20% of Veeva's total revenue, down from 25% two years ago, with the top 20 pharmaceutical clients accounting for about 50-60% of this CRM revenue segment [2]. - Stifel estimates that Veeva will face a 2-3% revenue headwind over the next five years due to these customer migrations, which is considered minor and not material [2]. Group 2: Competitive Landscape - KeyBanc Capital Markets downgraded Veeva from Overweight to Sector Weight, citing increasing competition in the CRM segment, particularly from Salesforce, which is gaining favor among large pharmaceutical clients [3]. - The shift in preference towards Salesforce's CRM offerings is seen as a significant concern for Veeva's future outlook [3]. Group 3: Company Overview - Veeva Systems Inc. provides cloud-based software solutions for the life sciences industry, including applications for regulatory compliance, clinical data management, and customer relationship management [4]. - The company has integrated AI into its platforms to enhance drug development and commercialization processes [4].

Core Viewpoint - Medtronic plc is highlighted as a promising healthcare AI stock following the FDA's approval of its HUGO robotic-assisted surgery system, which is expected to enhance its competitive position in the surgical robotics market [1][2]. Group 1: FDA Approval and Market Impact - The FDA granted regulatory approval for Medtronic's HUGO robotic-assisted surgery system, marking the end of a lengthy development phase and enabling competition in the US surgical robotics market [2][3]. - The HUGO system is intended for minimally invasive urologic surgical procedures, including prostatectomy, nephrectomy, and cystectomy [3][4]. - Stifel anticipates that significant revenue contributions from the HUGO launch will not materialize until Medtronic's fiscal year 2027 [2]. Group 2: Clinical Study and Launch Strategy - The approval of the HUGO system followed positive outcomes from the Expand URO investigational device exemption clinical study, which is noted as the largest multi-center prospective IDE trial for multi-port robotic-assisted urologic surgery in the US [4]. - Medtronic plans a phased launch of the HUGO system, focusing on partnerships with leading hospitals to facilitate its introduction into the market [4]. Group 3: Company Overview - Medtronic plc develops and manufactures a range of medical devices and therapies across various sectors, including cardiovascular, diabetes, surgical, and neurological care [5]. - The company's AI-enabled product portfolio includes GI Genius, Touch Surgery Enterprise for surgical video analysis, AiBLE for neurosurgery, and the MiniMed 780G insulin pump [5].

Siemens Healthineers Capital Markets Day Summary Company Overview - **Company**: Siemens Healthineers (OTCPK: SEMH.F) - **Event**: 2025 Capital Markets Day - **Date**: November 17, 2025 Key Points Industry Position and Strategy - Siemens Healthineers is recognized as a leader in the healthcare industry, particularly in imaging and precision therapies, with a strong presence in the Americas, Europe, China, and APJ regions [6][9][10] - The company operates in 70 countries and has an installed base of 700,000 systems, impacting 3 billion patients annually [6][7] - The focus is on elevating health globally, addressing non-communicable diseases (NCDs) which account for 75% of global deaths [17][18] Financial Performance - Revenue growth has averaged over 6% per year since the last capital market day, with EPS growth at 11% per year [10][58] - Siemens Healthineers reported revenues of over EUR 23 billion and EBIT close to EUR 4 billion [9] - The company has a backlog of over EUR 6 billion from value partnerships [8][12] Research and Development - Siemens Healthineers invests more than EUR 2 billion annually in R&D, with a focus on software, AI, and data science [7] - The company holds 1,300 patent families in healthcare AI, showcasing its commitment to innovation [7] Business Segments - The company operates in three synergistic business segments: Imaging, Varian (Precision Therapy), and Advanced Therapies, with Diagnostics following a separate path [9][13] - Diagnostics has improved margins by 8 percentage points since 2023 and is expected to have more entrepreneurial freedom for strategic growth [13] Future Growth and Targets - Midterm growth targets (2027-2030) include revenue growth of 5-9% and double-digit EPS growth [41][42] - The company aims for margin expansion of about 100 basis points per year in Precision Therapy and mid-single-digit growth in Diagnostics [42] - Sustainability targets include reducing carbon footprint by 90% in scope one and two by 2030 [42] Customer Challenges - Key challenges for customers include efficiency, clinical excellence, and access to care, driven by staff shortages and the need for improved healthcare systems [34][35][36] - Siemens Healthineers aims to address these challenges through value partnerships and innovative solutions [37][38] Technological Innovations - The company is focusing on personalized treatment approaches for NCDs, leveraging AI and advanced imaging technologies [22][23][24] - Innovations such as photon counting CT and AI-enabled MRI are positioned to enhance early detection and treatment planning [25][29] Capital Allocation and Financial Strategy - Siemens Healthineers has a stable dividend policy, proposing EUR 1.00 per share for the next AGM, with a commitment to maintain a progressive dividend [52] - The company targets a net debt to EBITDA ratio of 2.5 over the next two years, aiming for a strong investment-grade rating [54] Conclusion - Siemens Healthineers is well-positioned to tackle significant healthcare challenges through its innovative technologies, strong market presence, and strategic focus on growth and sustainability [39][40]

Capital Markets Day London, November 17, 2025 Unrestricted © Siemens Healthineers, 2025 1 Unrestricted © Siemens Healthineers, 2025 Capital Markets Day 2025 Safe Harbor Statement This webcast has been provided solely for use at this meeting. By attending the meeting or accessing this webcast, you agree to be bound by the following limitations. This webcast is provided in conjunction with an oral presentation and should not be taken out of context. This webcast serves for information purposes only and the in ...

Core Insights - Microsoft has transformed from a software leader to an AI powerhouse, with a focus on healthcare AI positioning it as a strong investment opportunity for 2025 [1] - The stock is currently trading at $524, reflecting a year-to-date gain of 24.5%, prompting discussions on whether to invest now or wait for a better entry point [1] Strategic Developments - The partnership with Harvard Medical School, set for October 2025, marks a significant shift in healthcare AI development, integrating Harvard Health Publishing content into Microsoft's Copilot AI [2] - This partnership aims to reduce reliance on OpenAI while enhancing proprietary healthcare capabilities, potentially generating substantial revenue streams [2] - Microsoft processes 50 million health-related queries daily, creating a competitive data advantage [2] Financial Performance - Microsoft reported $76.4 billion in revenues for Q4 fiscal 2025, an 18% year-over-year growth, with net income rising 24% to $27.2 billion [3] - Full fiscal 2025 revenues reached $281.7 billion, with operating income increasing 17% to $128.5 billion [3] - Azure cloud revenues exceeded $75 billion annually, growing 39% in the latest quarter, significantly driven by AI services [3] Product Innovations - The launch of Dragon Copilot in March 2025 represents a breakthrough in healthcare AI, combining voice AI with ambient listening, saving doctors five minutes per patient encounter [5] - The AI Diagnostic Orchestrator unveiled in June 2025 achieved 85% diagnostic accuracy on complex cases, significantly outperforming experienced physicians [6] Competitive Positioning - Microsoft operates as a trusted enterprise partner, fostering collaborations with major health systems, which enhances its investment appeal [7] - The 20-year partnership with Epic Systems provides distribution advantages that are difficult for new entrants to replicate [7] Market Outlook - The healthcare AI market is projected to grow from $37 billion in 2024 to $187 billion by 2030, indicating a 37% compound annual growth rate [15] - Microsoft's strategic positioning and financial strength suggest a favorable risk-reward balance for immediate investment [15] Valuation Considerations - Microsoft trades at a forward price-to-sales ratio of 11.68x, above the industry average of 8.69x, justified by its accelerating Azure growth and leadership in AI [9] - Despite competition from Amazon, Google, and Oracle, Microsoft's structural advantages support its premium valuation [11]